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Tumor cells and tumor infiltrating lymphocytes (TIL)
competes for glucose and other metabolites within the
tumor microenvironment for their survival. Glucose
consumption by tumors metabolically restricts T cell’s
ability to produce effector cytokines and therefore
approaches to improve the overall metabolic fitness of
TIL may improve tumor regression in cancer patients.
Long-term survival and anti-tumor immunity critically
depends on their metabolic fitness but approaches to
select metabolically robust T cells for adoptive immu-
notherapy remains less clear. Here we introduce a sim-
ple and clinically translatable method using a lipophilic
cationic dye (tetramethylrhodamine methyl ester-
TMRM) to identify and isolate metabolically-robust
T cells based on mitochondrial membrane-potential
(ΔΨm). Cells with lower membrane-potential (low-
ΔΨm) had a molecular profile characteristic of memory
precursors and displayed an enhanced ability to enter
the memory pool as compared to cells displaying higher
mitochondrial potential (high-ΔΨm) characteristic of
short-lived effectors. Interestingly, we also found that
multiple distinct negative inhibitory receptors such as
programmed death-1 (PD-1), cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), B- and T-lymphocyte
attenuator (BTLA), Lymphocyte-activation gene 3
(LAG-3) and T cell immunoglobulin mucin receptor 3
(TIM-3) were enriched in the high-ΔΨm subset com-
pared to the low-ΔΨm subset. Comprehensive metabo-
lomic and gene expression profiling demonstrated global
features of metabolic fitness in low ΔΨm sorted CD8+
T cells—including reduced glycolysis, enhanced fatty-
acid oxidation and robust spare respiratory capacity.
Transfer of low-ΔΨm T cells was associated with super-
ior long-term in vivo persistence as evidenced by 100
fold increase in the frequency of T cells 300 days after
adoptive transfer, augmented autoimmunity and an
enhanced capacity to eradicate established cancer com-
pared with high-ΔΨm cells. High-ΔΨm T cells exhibited
elevated ROS levels, increased effector cytokines and
had up-regulation of genes involved in DNA replication,
DNA repair and cell-cycle arrest genes compared to
low-ΔΨm T cells. Surprisingly, use of Ψm to enrich for
cells with superior metabolic features was observed
within central-memory (TCM) and effector (Tc17, Th1,
Th17) T cells as well as long-term hematopoietic stem
cells (LT-HSC). Finally, we also demonstrate that mito-
chondrial membrane potential based sorting can identify
CD45RO- CCR7+ human CD8+ T cells. These findings
demonstrate that metabolic-sorting serves as a comple-
mentary strategy to the use of conventional cell surface
markers for identifying cells with the capacity for long-
term survival and ongoing effector function after adop-
tive-transfer. This novel metabolism-based approach
may be broadly applicable to therapies involving transfer
of hematopoietic stem cells or lymphocytes for treat-
ment of viral-associated illnesses and advanced cancer.
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